PV Bulletin

PSUSA/00001088/202512 - Safety Update Amendments for Dimenhydrinate

Updates to product information regarding risks associated with caffeine/dimenhydrinate.

Primary source: View

PV Impact Brief

Urgency: HighConfidence: high

What changed

Product information must be amended to include warnings about misuse of dimenhydrinate, particularly among adolescents and young adults, as well as potential risks of Stevens-Johnson syndrome and fixed drug eruptions.

Why it matters

These changes are essential to ensure that safety information accurately reflects the risks associated with the product, thus protecting public health.

Action needed

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 28, 2026

Full briefing

Practical implication

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

The European Medicines Agency (EMA) has issued a periodic safety update report (PSUSA) that requires changes to product information for caffeine/dimenhydrinate regarding misuse, Stevens-Johnson syndrome, and fixed drug eruption risks.

What changed: Product information must be amended to include warnings about misuse of dimenhydrinate, particularly among adolescents and young adults, as well as potential risks of Stevens-Johnson syndrome and fixed drug eruptions.

Why it matters: These changes are essential to ensure that safety information accurately reflects the risks associated with the product, thus protecting public health.

Practical implication: Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

View original source

  • Source: EMA - What's new
  • Published at source: 2026-08-28T12:40:00.000Z
  • Discovered by monitor: 2026-08-29T05:25:08.255Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Reporting Requirement#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward